Kenneth Gene Draper

US Patent:

20020177568, Nov 28, 2002

Filed:

May 23, 2001

Appl. No.:

09/864785

Inventors:

Dan Stinchcomb - Ft. Collins CO, US
James McSwiggen - Boulder CO, US
Kenneth Draper - Reno NV, US

International Classification:

C07H021/04
A61K048/00

US Classification:

514/044000, 536/023200

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression or function of NFKB genes, such as REL-A, REL-B, REL (c-rel), NFKB1 (p105/p50) and NFKB2 (p100)/p52/p49).

US Patent:

20030068301, Apr 10, 2003

Filed:

Jun 8, 2001

Appl. No.:

09/877478

Inventors:

Kenneth Draper - Reno NV, US
Lawrence Blatt - Boulder CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US

International Classification:

A61K038/21
C07H021/02
A61K048/00

US Classification:

424/085600, 514/044000, 424/085700, 536/023100

Abstract:

Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed.

US Patent:

20030162264, Aug 28, 2003

Filed:

Dec 23, 2002

Appl. No.:

10/325403

Inventors:

James Thompson - Lafayette CO, US
Kenneth Draper - Reno NV, US

Assignee:

Ribozyme Pharmaceuticals, Inc.

International Classification:

C07H021/02
C12P019/34
C12N015/00
C12N005/06

US Classification:

435/091100, 435/325000, 536/023100, 435/320100

Abstract:

The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

US Patent:

20040054156, Mar 18, 2004

Filed:

Jan 15, 2003

Appl. No.:

10/342902

Inventors:

Kenneth Draper - Reno NV, US
Lawrence Blatt - Boulder CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US

International Classification:

C07H021/02
C12N005/08
A61K048/00

US Classification:

536/023100, 435/366000, 424/093210

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC (Lamivudine) and Interferons are disclosed.

US Patent:

20040127446, Jul 1, 2004

Filed:

Sep 23, 2003

Appl. No.:

10/669841

Inventors:

Lawrence Blatt - San Francisco CA, US
Dennis Macejak - Arvada CO, US
James McSwiggen - Boulder CO, US
David Morrissey - Boulder CO, US
Pamela Pavco - Lafayette CO, US
Patrice Lee - Erie CO, US
Kenneth Draper - Reno NV, US
Elisabeth Roberts - Federal Heights CO, US

International Classification:

A61K048/00
C07H021/02

US Classification:

514/044000, 536/023720

Abstract:

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV animal models and methods of use are disclosed, including methods of screening for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2′,5′-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV).

US Patent:

56228546, Apr 22, 1997

Filed:

Feb 7, 1994

Appl. No.:

8/192941

Inventors:

Kenneth G. Draper - Solon OH

Assignee:

Ribozyme Pharmaceuticals Inc. - Boulder CO

International Classification:

C12N 1585
C12Q 168
A61K 4800

US Classification:

435366

Abstract:

An enzymatic RNA molecule which specifically cleaves RNA of HTLV-1.

US Patent:

6017756, Jan 25, 2000

Filed:

Feb 7, 1994

Appl. No.:

8/193627

Inventors:

Kenneth G. Draper - Solon OH

Assignee:

Ribozyme Pharmaceuticals, Inc. - Cleveland OH

International Classification:

C12N 1585
C07H 1910

US Classification:

435325

Abstract:

An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis B virus.

US Patent:

62585851, Jul 10, 2001

Filed:

Feb 7, 1994

Appl. No.:

8/192946

Inventors:

Kenneth G. Draper - Solon OH

Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO

International Classification:

C12N 700
C07H 1910

US Classification:

4352351

Abstract:

An enzymatic RNA molecule which specifically cleaves an influenza virus RNA.

Address:

9615 Aidan Way, Reno, NV 89521

VIN:

JF1GD61667H516244

Make:

SUBARU

Model:

IMPREZA SEDAN NATL 2.0

Year:

2007